{"id":"low-heparin-molecular-weight","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LMWH is derived from unfractionated heparin through chemical or enzymatic depolymerization, resulting in shorter chain lengths. This modification provides more predictable pharmacokinetics and preferential anti-Xa activity over anti-IIa activity compared to unfractionated heparin. LMWH is used for thromboprophylaxis and treatment of thromboembolic disorders.","oneSentence":"Low molecular weight heparin (LMWH) inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:38.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Treatment of deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome anticoagulation"}]},"trialDetails":[{"nctId":"NCT07494877","phase":"","title":"Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-09-01","conditions":"Infertility","enrollment":300},{"nctId":"NCT04790370","phase":"PHASE4","title":"Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-08-02","conditions":"Pulmonary Embolism","enrollment":544},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT06753786","phase":"NA","title":"Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2024-10-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage","enrollment":200},{"nctId":"NCT07461545","phase":"NA","title":"Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS","status":"RECRUITING","sponsor":"Northern Jiangsu People's Hospital","startDate":"2026-02-04","conditions":"Cirrhosis, Splenectomy, Venous Thrombosis","enrollment":40},{"nctId":"NCT05672550","phase":"PHASE4","title":"Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-28","conditions":"Pediatric Kidney Transplant Recipients","enrollment":50},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT07299695","phase":"PHASE3","title":"Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"RECRUITING","sponsor":"Argyrios Tzouvelekis","startDate":"2026-01-25","conditions":"Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis","enrollment":196},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT07464808","phase":"NA","title":"Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2025-11-28","conditions":"Venous Thromboembolic Event","enrollment":25},{"nctId":"NCT07462182","phase":"NA","title":"Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction","status":"NOT_YET_RECRUITING","sponsor":"Muhammad Aamir Latif","startDate":"2026-04-01","conditions":"Intrauterine Growth Restriction","enrollment":108},{"nctId":"NCT07015905","phase":"PHASE3","title":"REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-06-25","conditions":"Venous Thromboembolism (VTE)","enrollment":2000},{"nctId":"NCT06454630","phase":"PHASE2","title":"A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-06-27","conditions":"Venous Thromboembolism","enrollment":179},{"nctId":"NCT03041805","phase":"","title":"Caprini Score in Venous Surgery: a Prospective Cohort Study","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-01-01","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":3000},{"nctId":"NCT03728166","phase":"NA","title":"Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-02-01","conditions":"Venous Thromboembolism","enrollment":400},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07140211","phase":"PHASE3","title":"Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis","status":"RECRUITING","sponsor":"Marc Blondon","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum","enrollment":9200},{"nctId":"NCT05498428","phase":"PHASE2","title":"A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-11-11","conditions":"Carcinoma, Non-small-Cell Lung","enrollment":520},{"nctId":"NCT01652209","phase":"PHASE3","title":"To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.","status":"COMPLETED","sponsor":"Pharmicell Co., Ltd.","startDate":"2013-09-01","conditions":"Acute Myocardial Infarction","enrollment":90},{"nctId":"NCT07388420","phase":"NA","title":"Adding Evolocumab to Conventional Lipid-lowering Therapy for Hypertriglyceridemia Induced Acute Pancreatitis","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2026-01-02","conditions":"Hypertriglyceridemia Induced Acute Pancreatitis","enrollment":40},{"nctId":"NCT07388056","phase":"","title":"Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2012-01-01","conditions":"Cancer-associated Thrombosis","enrollment":169},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT07384013","phase":"NA","title":"Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2025-11-01","conditions":"Oncologic Diseases, Coagulation Defect, Pain Management","enrollment":30},{"nctId":"NCT06243510","phase":"NA","title":"Comparison of Apixaban Versus Enoxaparin","status":"ENROLLING_BY_INVITATION","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-11-24","conditions":"Bladder Cancer","enrollment":90},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT07365670","phase":"NA","title":"Comparison of the Best Method for Measuring Anti-Xa Activity in Children Receiving Unfractionated Heparin in Cardiac Intensive Care (COMPAXE-HNF)","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2026-04-01","conditions":"Congenital Heart Disease, Unfractionated Heparin, Anti Xa Activity","enrollment":22},{"nctId":"NCT06382584","phase":"","title":"Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-01-01","conditions":"Direct Oral Anticoagulants (DOACs), Femoral Fractures, Surgery","enrollment":610},{"nctId":"NCT07361679","phase":"PHASE4","title":"LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention","status":"RECRUITING","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2023-01-18","conditions":"Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia","enrollment":100},{"nctId":"NCT06315530","phase":"PHASE2","title":"Effect of Telitacicept on Antibody Titers in Primary APS Patients","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2023-12-01","conditions":"Antiphospholipid Syndrome (APS)","enrollment":20},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT04273607","phase":"PHASE2, PHASE3","title":"Anticoagulation-free VV ECMO for Acute Respiratory Failure","status":"RECRUITING","sponsor":"Damian Ratano","startDate":"2022-09-01","conditions":"Extracorporeal Membrane Oxygenation Complication","enrollment":40},{"nctId":"NCT07124819","phase":"PHASE3","title":"Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Avexima Diol LLC","startDate":"2024-07-22","conditions":"Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE)","enrollment":215},{"nctId":"NCT04268940","phase":"","title":"Thrombo-Elastography Guided Management of ECMO","status":"COMPLETED","sponsor":"Damian Ratano","startDate":"2020-06-03","conditions":"Extracorporeal Circulation of Blood; Thrombocytopenia","enrollment":61},{"nctId":"NCT07140523","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA","status":"RECRUITING","sponsor":"Sirius Therapeutics Co., Ltd.","startDate":"2025-09-16","conditions":"Venous Thromboembolism","enrollment":450},{"nctId":"NCT07342127","phase":"","title":"Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-02-01","conditions":"Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy","enrollment":100},{"nctId":"NCT05569681","phase":"NA","title":"Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients","status":"RECRUITING","sponsor":"Hawler Medical University","startDate":"2023-01-07","conditions":"Morbid Obesity","enrollment":2400},{"nctId":"NCT07330661","phase":"NA","title":"Nursing-Led Deep Vein Thrombosis Prevention in Neurosurgery","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-01-01","conditions":"Deep Vein Thrombosis (DVT)","enrollment":1286},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT06937372","phase":"NA","title":"Delivery and Implementation of a Randomised Crossover Trial on Thrombosis","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-08-01","conditions":"Hip Fractures, Venous Thromboembolism (VTE)","enrollment":21194},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT07302620","phase":"","title":"HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-12-03","conditions":"Thromboembolic Disease","enrollment":70},{"nctId":"NCT05171075","phase":"PHASE3","title":"A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2022-09-27","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism","enrollment":417},{"nctId":"NCT05255003","phase":"PHASE4","title":"STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis","status":"RECRUITING","sponsor":"Tzu-Fei Wang","startDate":"2022-08-29","conditions":"Cancer-associated Thrombosis, Thrombocytopenia","enrollment":50},{"nctId":"NCT06628778","phase":"PHASE3","title":"Collaborative Risk-stratified Investigation in Teen Inpatients With Critical Illness: Anticoagulation With LMWH in Kids for ThromboProphylaxis (CRITICAL-Kids-TP)","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2026-10-31","conditions":"Venous Thromboembolism (VTE)","enrollment":802},{"nctId":"NCT06329921","phase":"NA","title":"Inpatient Monitoring of Unfractionated Heparin","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-06-26","conditions":"Blood Clot, Thrombosis","enrollment":2000},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07183605","phase":"NA","title":"Comparison of Heparin Anti-Xa Activity From Central Venous Catheter Samples Using a 5 mL Syringe Flush or a Vacuum Tube Flush Versus Peripheral Vein Samples in ICU Patients","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-09-22","conditions":"Anticoagulants and Bleeding Disorders","enrollment":30},{"nctId":"NCT02855047","phase":"","title":"The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2005-07","conditions":"Antiphospholipid Syndrome","enrollment":513},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT01588171","phase":"NA","title":"Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-05","conditions":"Venous Thromboembolic Diseases","enrollment":7020},{"nctId":"NCT05684796","phase":"NA","title":"Comparison of Two Pulmonary Embolism Treatments","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2023-11-27","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT05203705","phase":"PHASE2","title":"Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty","status":"TERMINATED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2022-03-07","conditions":"Prevention of Venous Thrombosis After TKA","enrollment":64},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04861103","phase":"PHASE4","title":"Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-10-01","conditions":"Pregnancy, High Risk, Anticoagulants","enrollment":12},{"nctId":"NCT05643885","phase":"","title":"A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-31","conditions":"Thromboembolism","enrollment":7304},{"nctId":"NCT07213713","phase":"","title":"Evaluation of Anti-Xa Activity in Patients With Severe Obesity After Subcutaneous Injection of Enoxaparin for Antithrombotic Prophylaxis at Two Different Sites.","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-10-01","conditions":"Venous Thromboembolism, Obese Patients","enrollment":80},{"nctId":"NCT07189897","phase":"PHASE4","title":"Apixaban or Enoxaparin After Head and Neck Cancer Surgery","status":"RECRUITING","sponsor":"Kiranya Arnold","startDate":"2025-10","conditions":"Venous Thromboembolism, Head and Neck Cancer","enrollment":76},{"nctId":"NCT07195955","phase":"NA","title":"Cold Spray for Pain and Ecchymosis After Anticoagulant Prophylaxis in Orthopedic Surgery","status":"COMPLETED","sponsor":"Kocaeli University","startDate":"2024-02-01","conditions":"Nursing Care, Cold Application, Pain","enrollment":101},{"nctId":"NCT03244020","phase":"PHASE4","title":"LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2018-02-16","conditions":"Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma","enrollment":2868},{"nctId":"NCT07200674","phase":"","title":"Interest of High-speed Centrifugation for Measuring Anti-Xa Activity on Lipemic Plasma","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2024-03-11","conditions":"Hypertriglyceridemia","enrollment":150},{"nctId":"NCT06180889","phase":"PHASE2","title":"Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Alphamab Co., Ltd.","startDate":"2023-12-20","conditions":"Knee Arthroplasty, Total","enrollment":241},{"nctId":"NCT07168005","phase":"NA","title":"Informative Video Before LMWH Postpartum - Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2025-10-15","conditions":"Venous Thromboembolism (VTE), Postpartum Care, Anxiety","enrollment":160},{"nctId":"NCT06776159","phase":"NA","title":"The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2025-06-24","conditions":"CVD - Cardiovascular Disease, Bruise, Pain","enrollment":180},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT06118957","phase":"PHASE2","title":"Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-10-11","conditions":"Thromboembolism","enrollment":64},{"nctId":"NCT05618808","phase":"PHASE2","title":"A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-05-24","conditions":"Venous Thromboembolism","enrollment":373},{"nctId":"NCT06913595","phase":"PHASE1","title":"Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2024-03-25","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT05625932","phase":"PHASE3","title":"TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Galician Research Group on Digestive Tumors","startDate":"2023-03-02","conditions":"Colorectal Cancer Metastatic, Thromboembolism","enrollment":232},{"nctId":"NCT05576766","phase":"NA","title":"Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-09","conditions":"Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol","enrollment":54},{"nctId":"NCT07132515","phase":"PHASE4","title":"Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2023-08-15","conditions":"Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT04762992","phase":"PHASE3","title":"LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)","status":"ENROLLING_BY_INVITATION","sponsor":"Centro Hospitalar de Lisboa Central","startDate":"2022-07-18","conditions":"Fetal Growth Retardation, Prematurity, Pre-Eclampsia","enrollment":12},{"nctId":"NCT02066454","phase":"PHASE3","title":"Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2014-06-05","conditions":"Myeloma, Venous Thromboembolism","enrollment":108},{"nctId":"NCT06484231","phase":"","title":"Evaluation of the Effectiveness of Prophylactic LMWH by Thromboelastography","status":"COMPLETED","sponsor":"Ege University","startDate":"2023-07-24","conditions":"Malignancy","enrollment":25},{"nctId":"NCT06991530","phase":"","title":"Effect of Low Molecular Weight Heparin in Freeze-thaw Embryo Transfer Cycles in Women With Recurrent Implantation Failure","status":"COMPLETED","sponsor":"The Second Hospital of Shandong University","startDate":"2021-01-01","conditions":"Low Molecular Weight Heparin, Recurrent Implantation Failure, FET","enrollment":392},{"nctId":"NCT07116239","phase":"NA","title":"Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-09","conditions":"Nephrotic Syndrome, Hypoalbuminemia","enrollment":60},{"nctId":"NCT05554055","phase":"","title":"Correlation Between LR-ACT and Anti Xa Activity During Endovascular Surgery Procedures. AXAES (Anti Xa vs ACT-LR in Endovascular Surgery)","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-11","conditions":"Aortic Diseases, Arterial Disease, Thrombosis","enrollment":""},{"nctId":"NCT06004674","phase":"PHASE2","title":"Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2023-12-26","conditions":"Adverse Pregnancy Outcome","enrollment":20},{"nctId":"NCT06712004","phase":"PHASE2","title":"A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-02-10","conditions":"Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction","enrollment":40},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT06515730","phase":"PHASE4","title":"Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2025-04-08","conditions":"Left Ventricular Thrombus, Acute Myocardial Infarction","enrollment":212},{"nctId":"NCT06480994","phase":"","title":"Exclusion of Venous Thrombo-Embolism With a New Clinical Decision Support","status":"RECRUITING","sponsor":"Diagnostica Stago R&D","startDate":"2022-06-21","conditions":"Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis","enrollment":1836},{"nctId":"NCT03045406","phase":"PHASE3","title":"Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer","status":"COMPLETED","sponsor":"Fadoi Foundation, Italy","startDate":"2017-04-13","conditions":"Venous Thromboembolism","enrollment":1170},{"nctId":"NCT06875518","phase":"NA","title":"Comparative Study of Blood Loss in Total Laparoscopic Hysterectomy by Ligation the Uterine Arteries in Different Techniques.","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-03-12","conditions":"Gynecologic Disease","enrollment":60},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT04504318","phase":"PHASE1, PHASE2","title":"Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT","status":"COMPLETED","sponsor":"Stanford University","startDate":"2020-08-12","conditions":"Venous Thromboembolism","enrollment":82},{"nctId":"NCT04997265","phase":"NA","title":"Strategies for Anticoagulation During Venovenous ECMO","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-05-12","conditions":"Acute Hypoxemic Respiratory Failure, Anticoagulant-induced Bleeding, Thromboembolism","enrollment":26},{"nctId":"NCT06884384","phase":"","title":"DOAC Versus VKA in Patients With Non-high-risk APS : Prospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-09-15","conditions":"Antiphospholipid Syndrome (APS), Cohort Study, Thrombotic and Bleeding Events","enrollment":310},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT06868823","phase":"","title":"Prospective Observational Pilot Study of LMWH Versus UFH as ECMO Anticoagulation in Lung Transplantation","status":"RECRUITING","sponsor":"University Hospital, Motol","startDate":"2025-05-01","conditions":"Lung Transplantation, Extracorporeal Membrane Oxygenation (ECMO), Anticoagulants and Bleeding Disorders","enrollment":40},{"nctId":"NCT02887820","phase":"NA","title":"Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)","status":"TERMINATED","sponsor":"Stephen Esper","startDate":"2017-12-15","conditions":"Heart Disease, Lung Disease","enrollment":15},{"nctId":"NCT04741464","phase":"NA","title":"Effect of Tinzaparin on Inflammatory Biomarkers During the Acute Phase of Deep Vein Thrombosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-02-02","conditions":"Deep Vein Thrombosis, Inflammatory Response","enrollment":9},{"nctId":"NCT05634057","phase":"NA","title":"Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis","status":"RECRUITING","sponsor":"Chen Ying","startDate":"2024-01-25","conditions":"Sepsis","enrollment":782},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT04536272","phase":"PHASE3","title":"Reduced Anticoagulation Targets in ECLS (RATE)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2020-10-01","conditions":"Heart Failure, Respiratory Failure, Extracorporeal Membrane Oxygenation","enrollment":330},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT06689241","phase":"NA","title":"Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2024-10-01","conditions":"Morbid Obesity, Bariatric Surgery Candidate","enrollment":162},{"nctId":"NCT00203970","phase":"","title":"Diffusion of Use of Low Molecular Weight Heparin for Thrombosis on the Medicine Services","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2001-02","conditions":"Thrombosis","enrollment":645}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Low Heparin Molecular Weight","genericName":"Low Heparin Molecular Weight","companyName":"University Hospital, Angers","companyId":"university-hospital-angers","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low molecular weight heparin (LMWH) inhibits blood coagulation by enhancing the activity of antithrombin III, which inactivates clotting factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome anticoagulation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}